1. Home
  2. SABR vs EVO Comparison

SABR vs EVO Comparison

Compare SABR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABR
  • EVO
  • Stock Information
  • Founded
  • SABR 2006
  • EVO 1993
  • Country
  • SABR United States
  • EVO Germany
  • Employees
  • SABR N/A
  • EVO N/A
  • Industry
  • SABR Computer Software: Programming Data Processing
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SABR Technology
  • EVO Health Care
  • Exchange
  • SABR Nasdaq
  • EVO Nasdaq
  • Market Cap
  • SABR 1.2B
  • EVO 1.2B
  • IPO Year
  • SABR 2014
  • EVO 2021
  • Fundamental
  • Price
  • SABR $1.85
  • EVO $3.47
  • Analyst Decision
  • SABR Buy
  • EVO Buy
  • Analyst Count
  • SABR 5
  • EVO 2
  • Target Price
  • SABR $4.12
  • EVO $5.40
  • AVG Volume (30 Days)
  • SABR 6.4M
  • EVO 46.8K
  • Earning Date
  • SABR 10-30-2025
  • EVO 11-05-2025
  • Dividend Yield
  • SABR N/A
  • EVO N/A
  • EPS Growth
  • SABR N/A
  • EVO N/A
  • EPS
  • SABR N/A
  • EVO N/A
  • Revenue
  • SABR $3,010,157,000.00
  • EVO $912,894,891.00
  • Revenue This Year
  • SABR N/A
  • EVO $0.43
  • Revenue Next Year
  • SABR $4.17
  • EVO $9.72
  • P/E Ratio
  • SABR N/A
  • EVO N/A
  • Revenue Growth
  • SABR 6.13
  • EVO N/A
  • 52 Week Low
  • SABR $1.69
  • EVO $2.84
  • 52 Week High
  • SABR $4.63
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • SABR 41.43
  • EVO 41.34
  • Support Level
  • SABR $1.70
  • EVO $3.40
  • Resistance Level
  • SABR $1.83
  • EVO $3.55
  • Average True Range (ATR)
  • SABR 0.07
  • EVO 0.07
  • MACD
  • SABR 0.06
  • EVO 0.02
  • Stochastic Oscillator
  • SABR 84.21
  • EVO 42.31

About SABR Sabre Corporation

Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: